Agrawal, Manasi http://orcid.org/0000-0003-4729-1485
Allin, Kristine H. http://orcid.org/0000-0002-6880-5759
Mehandru, Saurabh http://orcid.org/0000-0001-9781-2969
Faith, Jeremiah
Jess, Tine http://orcid.org/0000-0002-4391-7332
Colombel, Jean-Frederic http://orcid.org/0000-0001-6472-249X
Article History
Accepted: 29 March 2023
First Online: 20 April 2023
Competing interests
: M.A. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK129762-02). S.M. has received research grants from Genentech and Takeda; payment for lectures from Genentech, Morphic and Taleda; and consulting fees from Arena Pharmaceuticals, Ferring, Morphic and Takeda. J.F. has received consulting fees from Vedanta Biosciences. J.-F.C. has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire and Takeda; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix and Vifor; and holds stock options in Intestinal Biotech Development. The other authors declare no competing interests.